# TB-500 Side Effects: What the Research Shows

> TB-500 side effects documented in research include injection site reactions, potential pro-angiogenic cancer risk, immune modulation, and product purity concerns. Full safety review — all cited, all gaps noted.

The TB-500 side effects and safety profile are a mixed record of favorable short-term animal observations and substantial unresolved questions. No systematic human adverse-event study for injectable TB-500 (Ac-LKKTETQ) exists.

## Reported Side Effects of TB-500

**Injection site reactions.** Mild redness, swelling, or discomfort at the injection site is the most consistently reported side effect across user observations and animal studies. Severity appears low; systemic reactions are uncommon.

**Transient systemic effects.** Transient fatigue, mild nausea, and dizziness have been reported anecdotally. No controlled study has quantified these for the TB-500 fragment.

**Phase I Tβ4 data (parent protein only).** The full-length Tβ4 protein (IV, 54 healthy volunteers) showed no serious adverse events and no dose-limiting toxicities [16]. This data covers the parent protein, not the TB-500 fragment.

A 2026 Sports Medicine review confirmed that rigorous human safety data for TB-500 are "scarce" and that the gray market supply chain presents "potential for serious harm to patients" [20].

## Is TB-500 Safe? Reviewing the Current Evidence

No human clinical trials have evaluated injectable TB-500 safety. The FDA classifies TB-500 as a Category 2 bulk drug substance, prohibiting pharmaceutical compounding for humans. WADA prohibits it in competitive sport.

The honest summary: preclinical evidence is reassuring about short-term tolerability; long-term human safety is undocumented [20].

## Long-Term Safety: Current Evidence Gaps

The longest preclinical data point is a 6-month dystrophic mouse study showing no overt toxicity [11]. No multi-year human cohort data exists. Absence of reported harms in uncontrolled settings is not evidence of long-term safety.

## TB-500 and Cancer Risk: What Angiogenesis Research Shows

TB-500 promotes angiogenesis via VEGF upregulation — the same pathway exploited by tumors.

1. **Mouse melanoma model:** Tβ4 overexpression produced 4.3× more lung metastases, 4.4× greater tumor blood vessel formation, and tumors 63% larger than controls [12].
2. **HIF-1alpha/VEGF pathway:** In human colon cancer tissue and mouse tumor cell lines, Tβ4 stabilizes HIF-1alpha protein, directly inducing VEGF expression [13].
3. **Pancreatic cancer cell lines:** Tβ4 overexpressed 3.7–4.5-fold vs. normal ductal epithelium; activated JNK pathways promoting tumor cell survival [14].

No human study confirms or rules out cancer promotion from exogenous TB-500. Researchers formally flag this as unresolved.

## TB-500 Immune System Effects

Tβ4 suppresses TNF-alpha-driven NF-κB activation and IL-8 expression [15]. It promotes macrophage M2 polarization in mouse NAFLD models [22]. This bidirectional activity — pro- and anti-inflammatory depending on context — underlies theoretical concerns about immune dysregulation. No human autoimmune events have been formally reported. Phase I Tβ4 data showed low anti-drug antibody rates (0.9–1.8%) [16].

## Injection Site Reactions

Mild redness, swelling, or discomfort. Severity appears low. No controlled study has systematically characterized injection site reaction incidence for TB-500 in any species.

## Research-Grade Purity and Contaminant Risks

A 2023 analytical study found commercially available TB500/TB1000 products are "not systematically consistent with their descriptions" [17]. Contamination risks — bacterial endotoxins, incorrect peptide sequences, heavy metals, undisclosed excipients — are independent of the compound's pharmacology.

## References

[11] Spurney CF, et al. Chronic Thymosin β-4 in the dystrophin-deficient mouse. PLoS One. 2010.
[12] Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003.
[13] Jo JO, et al. Thymosin β4 induces VEGF expression via HIF-1α. Biochim Biophys Acta. 2010.
[14] Zhang Y, et al. Thymosin Beta 4 is Overexpressed in Human Pancreatic Cancer Cells. Cancer Biol Ther. 2007.
[15] Qiu P, et al. Thymosin β4 inhibits TNF-α-induced NF-κB activation. PLoS One. 2011.
[16] Wang X, et al. Phase I study of recombinant human thymosin β4. J Cell Mol Med. 2021.
[17] Delcourt V, et al. TB500/TB1000 and SGF1000. Drug Test Anal. 2023.
[20] Mendias CL, Awan TM. Safety and Efficacy of Unapproved Peptide Therapies. Sports Medicine. 2026.
[22] Zhu Z, et al. Thymosin β4 promotes M2 polarization in NAFLD. J Inflamm Res. 2025.
[23] Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye. Clin Ophthalmol. 2015.

---

Peer-reviewed findings on TB-500, read warmly and honestly — the evidence gaps are noted alongside the findings, and no clinic sits behind this page.